MedTrace Logo

International Surveillance of Antimicrobial Resistance in Cirrhosis-Related Infections

NCT06634940 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-10-10

No results posted yet for this study

Summary

What is this study about?

This study tracks antibiotic resistance in patients with cirrhosis who develop bacterial infections. Cirrhosis is a condition where the liver is severely scarred, and people with cirrhosis are at high risk for serious bacterial infections.

Why is this study important?

Bacterial infections are common in patients with cirrhosis, affecting 25-46% of those who are hospitalized. These infections can be life-threatening, with 1 in 4 patients dying from complications. Many of these infections are becoming harder to treat because the bacteria are resistant to antibiotics. Infections caused by resistant bacteria are increasing, which makes finding the right antibiotic quickly even more difficult.

In other regions of the world, guidelines exist to help doctors choose the right antibiotics for cirrhosis patients. However, in Latin America, we don't have specific guidelines for our region, and doctors currently rely on recommendations from the U.S. or Europe. These guidelines may not reflect the local patterns of bacterial infections and resistance we see here.

What is the goal of this study?

The main goal of this study is to create a long-term system to track how bacteria respond to antibiotics in patients with cirrhosis in Latin America. By collecting data from hospitals across different countries, we aim to:

* Identify how many infections are caused by multidrug-resistant bacteria.
* Understand how antibiotics (such as ceftriaxone, vancomycin, and carbapenems) act against these infections.
* Generate reports informing bacterial resistance patterns to help doctors make better patient treatment decisions.

What do we hope to achieve?

We hope the data we collect will help develop guidelines for patients with cirrhosis in Latin America. These guidelines will ensure that doctors use the most effective antibiotics based on real-time data from our region. This should improve patient outcomes and help prevent the spread of resistant bacteria.

Conditions

Sponsors & Collaborators

  • Hospital Italiano de Buenos Aires

    lead OTHER

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-15
Primary Completion
2030-12-01
Completion
2031-06-01

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06634940 on ClinicalTrials.gov